Dr Thomas Newsom-Davis a Consultant Medical Oncologist at Chelsea and Westminster Hospital. He specialises in thoracic malignancies, especially lung cancer and mesothelioma. In 2015, he was awarded the Macmillan Innovation Excellence Award.

Training

Dr Newsom-Davis completed his training at University College and Middlesex School of Medicine, London, in 1998, including First Class honours for his BSc. He went on specialise in medical oncology at Charing Cross and Hammersmith Hospitals and completed a PhD in tumour immunology. He was appointed to Chelsea & Westminster Hospital in 2010.

Current Roles

Dr Newsom-Davis leads the lung cancer service for Chelsea & Westminster Hospital, and is Vice Chair of the British Thoracic Oncology Group (BTOG) Steering Committee, an organistion which supports and educates thoracic oncology profressionals across the United Kingdom. Dr Newsom-Davis is Chair of the Harley Street Clinic lung cancer multidisciplinary team (MDT), and Chair of the HCA Healthcare UK Thoracic Oncology Board.

Research

Dr Newsom-Davis has an active clinical trial portfolio, and has presented his work at National and International meetings. He has been an invited lecturer for organisations including the Royal College of Physicians, European Society of Medical Oncology, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Diseases, Medical Tests and Treatments

• Immunotherapy, Targeted Therapy, Chemotherapy
• Lung Cancer
• Mesothelioma

Dr Naomi Fersht is a consultant clinical oncologist at University College Hospital and the National Hospital for Neurology and Neurosurgery. She specialises exclusively in the management of primary and secondary brain and spinal tumours. This involves the use of both conventional and innovative radiotherapy techniques and chemotherapy.

Her special interests are brain oligometastases; meningiomas; pituitary tumours; the management of teenagers and young adults with brain tumours; and advanced radiotherapy techniques including radiosurgery.

She qualified from the University of Cambridge and her specialist training was at the Royal Marsden and University College Hospitals. Naomi's doctoral thesis, supervised by Nobel Laureate Sir Paul Nurse, was in cell cycle checkpoints.

• Brain oligometastases
• Meningiomas
• Pituitary tumours
• The management of teenagers and young adults with brain tumours (age 16-24)
• Advanced radiotherapy techniques including radiosurgery

Professor Elinor Sawyer is a Consultant Clinical Oncologist with a specialist interest in the treatment of breast cancer. She is based at Guy’s & St Thomas’ Hospital but also performs private work and is Professor in Oncology at King’s College London.

She completed her clinical oncology training at University College London, Royal Free and St Thomas’ Hospitals. Following this, she obtained her PhD in molecular genetics of cancer at the London Research Institute. In 2005 she was appointed as a Consultant Oncologist at Guy’s & St Thomas’ Hospital.

As well as her clinical practice, Professor Sawyer is heavily involved in research and her work has been published in a number of peer reviewed journals. Her main areas of research include genetic predisposition to breast cancer, particularly lobular breast cancer and pre invasive cancer (DCIS and LCIS), and identification of biomarkers that predict progression of early breast cancer.

• Chemotherapy 
• Immunotherapy 

• Breast Cancer 

Dr Tom Richards is a consultant clinical oncologist specialising in the treatment of gastrointestinal (GI) and breast cancers. He is the clinical lead of the GI and breast cancer radiotherapy units at University College London NHS Hospital (UCLH) and honorary consultant in Clinical Oncology at The Whittington NHS Hospital. Prior to his appointment at UCLH, he was Clinical Oncology consultant in the GI and breast units at St Bartholomew's and The Royal London NHS Hospitals.

He is an experienced oncologist treating oesophagus, stomach, liver, pancreaticobiliary, colorectal and breast cancers. His specialist expertise is the delivery of radiotherapy, chemotherapy and biological targeted drugs for cancers at these sites. His particular interest is in technical radiotherapy treatments using cyberknife and intensity-modulated radiotherapy and motion management techniques using 4D-CT radiotherapy planning, deep inspiratory breath-hold and image-guided radiotherapy.

After graduation from Imperial College School of Medicine in London, his subsequent general internal medicine training was at King's College Hospital, London. He undertook specialist oncology training at St Bartholomew's and The Royal Marsden Hospitals in London. In 2015 he was awarded a PhD from the University of London for clinical and translation research performed at The Institute of Cancer Research, King's College London and The Royal Marsden Hospital. He studied the mechanisms by which therapeutic radiation affects normal tissues and strategies to detect and reduce late toxicity after curative treatment. He was awarded the Johnson and Johnson clinical research prize in 2012 for work contributing to his PhD.

He is a fellow of the Royal College of Radiologists and a member of The Royal College of Physicians, ESMO and ESTRO. He has spoken and chaired sessions at numerous national and international meetings. He is course tutor and examiner for the Institute of Cancer research MSc course and is the local principal investigator for several GI cancer clinical trials. Dr Richards is passionate to improve cancer outcomes, develop clinical research and deliver innovative multi-modality cancer treatments.

• Radiotherapy
• Chemotherapy
• SABR/Cyberknife
• Intensity-modulated radiotherapy
• SIRT (internal liver-directed radiotherapy)

• Breast cancer
• Colon cancer
• Rectal cancer
• Anal cancer
• Oesophageal cancer
• Liver cancer
• Pancreatico-biliary cancer

Dr Hadaki is an experienced Consultant Oncologist who treats all stages of breast cancer.

He completed his specialist oncology training at Addenbrooke’s Teaching Hospital which has strong affiliations to the University of Cambridge. During his training, he completed the Royal College of Radiologist membership exam to proudly become one of its fellowships.

Dr Hadaki has been practising as a consultant since 2012 and has a very successful private practise in addition to his large well-established NHS practice.

Dr Hadaki is skillfully able to combine (where appropriate) the following treatment modalities to offer a complete and state of the art personalised cancer treatment service:

• Chemotherapy
• External beam radiotherapy (including IMRT and IGRT)
• Biological and targeted therapies
• Immunotherapies
• Stereotactic radiotherapy (SBRT, SABR, Cyberknife)
• Next-generation sequencing and molecular analysis of tumours
• Chemotherapy sensitivity testing
• Access to clinical trials
• Access to local ablative therapies (radiofrequency ablation, microwave ablation)
• Access to alternative therapies
• Access to palliative care services

Dr Hadaki also works with some of the most skilled surgeons in the country. All treatment plans are discussed at multidisciplinary team meetings.

Dr Hadaki is registered and compliant with the majority of private medical insurers including BUPA, BUPA International, AXA, Aviva, Vitality, WPA and others.

Dr Hadaki is able to treat international and self-paying patients. Embassy sponsored patients must have a letter of guarantee before any consultation or commencing treatment.

Self-paying patients should contact us directly for a quotation.

• Breast Cancer
• Lung Cancer
• Chemotherapy
• Immunotherapy
• Radiotherapy
• Stereotactic ablative radiotherapy (SABR)
• Oncology

• Breast Cancer

Professor Nutting is providing COVID-safe telephone and video consultations for cancer patients requiring a second opinion during this difficult time.

Professor Christopher Nutting is a Consultant Clinical Oncologist based at The Royal Marsden Chelsea and Sutton, where he has both a private and NHS practice. 

Professor Nutting completed his undergraduate training at the University of London in 1992 and he went on to become a member of the Royal College of Physicians and a Fellow of the Royal College of Radiologists. Professor Nutting qualified as an oncologist and achieved a Medical Doctorate at The Institute of Cancer Research, University of London.

Professor Nutting has a special interest in medical education and in 2001 he was appointed Honorary Senior Lecturer in Clinical Oncology at The Institute of Cancer Research. In 2002 he assumed the role of Teacher at the University of London and Head of the Head and Neck Unit at The Royal Marsden.

Professor Nutting is National Clinical Lead in Head and Neck Cancer for the UK Department of Health and the Cancer Services Collaborative. He is also President of the British Oncological Association and Chairman of the National Cancer Research Institute Committee for Head and Neck Cancer Research.

Professor Nutting is heavily involved in research trials and he has published over 300 research articles in his speciality.

• Chemotherapy
• Radiotherapy
• Intensity-modulated radiotherapy
• Radioiodine treatment
• Cyberknife

• Head and neck cancers
• Mouth cancer
• Throat cancer
• Thyroid cancer
• Lung cancer
• Skin cancer

I am a Medical Oncology Consultant for the Gastrointestinal Oncology Service at University College London Hospitals NHS Foundation Trust and Honorary Associate Professor at the UCL Cancer Insitute. I treat oesophageal, stomach, small bowel, colorectal and hepatobiliary cancers, as well as cancers of unknown primary. I am the UCLH Clinical Lead for the Cancer of Unknown Primary (CUP) Service and the Acute Oncology Service.

My research interests include immunotherapy for GI malignancies and Cancer of Unknown Primary, with focus on clinical trials and translational research of these cancers. I am Chief Investigator or Principal Investigator for a number of  GI or CUP immuno-oncology Phase 2 and 3 trials, including KEYNOTE 177, KEYNOTE 859, KEYNOTE 811, KEYNOTE 975,  VESTIGE, POLEM and CUPISCO.

I am Chair of the NCRI MUO-CUP Workstream as part of the Living With and Beyond Cancer CSG, and a member of the NCRI Colorectal Advanced and Adjuvant Disease Subgroup. I am the Principal Investigator of the UCL-UCLH GI + CUP Cancer Translational Research Biobank and a collaborator with the GI Oncology and CUP subgroups at the UCL Cancer Institute and Francis Crick Institute. I am a member of ASCO, ESMO and the Association of Cancer Physicans (UK).

I strongly believe in clinicians being educators and enjoy teaching oncology to UCL medical students, oncology and non-oncology junior trainees. I also give talks nationally and abroad at conferences and other hospitals to share best practice and future perspectives in the fields of GI oncology research, CUP, immunotherapy and novel trial designs.

To make an appointment or enquiry please contact my secretary Alanna Sarwar on asarwar@theloc.com or +44207 317 2659.

• Gastrointestinal Oncology - oesophageal, stomach, hepatobiliary and bowel cancers
• Cancer of Unknown Primary
• Acute Oncology
• Chemotherapy
• Targeted therapy
• Immunotherapy
• Clinical Trials

• Immunotherapy
• Gastrointestinal Oncology Research 
• Cancer of Unknown Primary Research 
• Molecular Profiling with solid and liquid biopsies
• Biomarker Driven Clinical Trial Design and Implementation

Dr Jonathan Shamash is a Consultant Oncologist and is the Lead in Acute Oncology at St Bartholomew’s Hospital and has a further NHS base at Queen’s Hospital, Romford. Dr Shamash also sees patients privately, including at Leaders in Oncology Care. He graduated from the University of Edinburgh in 1987 and then undertook post graduate training in London, gaining an MD in in-vitro modelling of lymphoma.

Dr Shamash sub-specialises in genito-urinary cancers and thoracic malignancies. He has a special interest in managing complex oncology problems and delivering intensive treatments, including high dose Interleukin-2 and high does chemotherapy in testicular cancer. . Dr Shamash also chairs the supra-regional germ cell tumour multidisciplinary meeting and is a member of the NCRI testis clinical studies group. He leads various clinical studies in the management of testicular and prostate cancer and has published widely.

Deborah Enting is a Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust and an Honorary Senior Lecturer at King's College London.

She undertook her medical training at the University of Groningen in The Netherlands and trained in Medical Oncology at Guy's and St George's Hospitals. She was a research fellow at the Department of Immunobiology at King's College London and in collaboration with colleagues of the Translational Oncology Urology Research (TOUR) group at KCL she works on tumour immune surveillance and bladder cancer research.

Deborah is a Medical Oncologist specialising in the treatment of Urological Cancers and the systemic treatment (chemotherapy, immunotherapy and targeted therapies) for bladder, prostate, kidney and testicular cancers. She is a national lead on a number of clinical trials including the IRONMAN prostate cancer registry study.

• Bladder cancer
• Prostate cancer
• Kidney cancer
• Testicular cancer

• Bladder cancer
• Prostate cancer
• Kidney cancer
• Testicular cancer

Dr Asad Qureshi is a Consultant Clinical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust. In his NHS and private practice, he specialises in the treatment of upper and lower gastro-intestinal and non-melanoma skin cancers: Oesophageal Cancer, Stomach Cancer, Colon Cancer, Rectal Cancer, Radiotherapy for non-melanomatous skin cancer, Chemotherapy and SABR. Dr Qureshi is the Clinical Lead for out-patients in the Cancer Centre at Guy’s Hospital, London and is a member of the Senior Oncology Management Team. He is also the Clinical Oncology and Radiotherapy Audit Lead and the Clinical Oncology Oesophago-gastric lead.

He trained at St Bartholomew’s and The Royal London Hospitals medical schools where he gained a BSc in neurosciences. He completed his specialist training in Clinical Oncology at a number of specialist departments in London, including Guy’s and St Thomas’ Hospital, Charing Cross Hospital, St Bartholomew’s Hospital and The Royal Marsden Hospital. During his training spent two years working in the Imaging Sciences Laboratories at Kings College London, and the Centre for Medical Image Computing at University College London assessing novel radiotherapy techniques for the treatment of mobile tumours. Dr Qureshi plays an active role in research and is a Principle Investigator on a number of national clinical trials. His research interests include Stereotactic Radiotherapy (SABR), Image-guided Radiotherapy (IGRT) and dose escalation of radiotherapy and he has published a number of papers in this field.Dr Qureshi is committed to medical education. He is a clinical and educational supervisor for Clinical Oncology trainees at Guy’s and St Thomas’ NHS Foundation Trust. He is also a Medical Supervisor for radiographers on prescribing courses.

• External Beam Radiotherapy (IMRT and IGRT)
• Chemotherapy
• Radiotherapy
• Stereotactic Radiotherapy (Including CyberKnife)

• Colorectal Cancer
• Anal Cancer
• Oesophageal Cancer
• Gatro-intestinal Cancers
• Stomach Cancer